Smarter Studies. Global Impact. Better Health.
The MRC Clinical Trials Unit (MRC CTU) at UCL is at the forefront of resolving internationally important questions in infectious diseases and cancer, and delivering swifter and more effective translation of scientific research into patient benefits.
Latest News and Updates
20 achievements from 20 years: The START trial shows it’s best to start HIV treatment as soon as possible
While many of our studies have changed policy and practice, few have had as fast an impact as the START study. At the same conference the START trial results were first presented, the World Health Organisation announced …
Intensified antiretroviral therapy does not reduce deaths among people starting HIV treatment with advanced disease
Adding a fourth drug, from a different class, to standard triple-drug antiretroviral therapy for the first 12 weeks for people starting HIV treatment with advanced disease, does not reduce deaths, according to the resul…
An infusion of ready-made influenza antibodies had no benefit overall for patients with influenza
Treatment with an infusion of influenza antibodies did not have any benefit overall after seven days for patients with influenza, according to results from the FLU-IVIG study, presented today at the 6th International Soc…
20 achievements from 20 years of MRC CTU: The TEMPER study and clinical trial monitoring
Making trials as efficient and effective as possible protect trial participants better, ensure reliable results and mean that new treatments can reach the general public more quickly. The TEMPER study was one of the larg…
Our Research Themes
Cancer
Innovative clinical trial design and meta-analysis extending beyond the boundaries of single cancer types
Infections
Major international clinical trials answering questions of global public health significance
Methodology
Development of methods with direct impact on the design, conduct and analysis of studies
Our Latest Tweets
-
#TBT - PROMIS shows MRI scan could help a quarter of men safely avoid prostate biopsy https://t.co/yJ7WentEDt
-
#Publication - Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer https://t.co/9sxI7VPsU4
-
The ARREST (Adjunctive Rifampicin to Reduce Early mortality from STaphylococcus aureus bacteraemia) trial found that adding rifampicin to standard antibiotic treatment for adults with S. aureus does not provide an overall benefit #clinicaltrials https://t.co/6uFVxf3ACd
